Sobi
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Sweden · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
Tomtebodavägen 23a, Stockholm, Stockholm...Phone Number
+46 86972000Website
www.sobi.comRevenue
$3 BillionStock Symbol
SOBIIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sobi
Sobi, founded in 2010 and based in Stockholm, Sweden, is an international biopharmaceutical company. Sobi has a research focus on therapies in hematology, immunology, and more.Explore more
Sobi Org Chart
BD
Medical Affairs, Gout Portfolio Head
Ed
Executive Director & Head of Clinical Study M...
SR
Senior Director, Clinical Operations
CS
Director, National, Immunology Field Medical
EA
Director, Regulatory Patient Access Middle , ...
JL
Director, Search and Evaluation
MA
Medical Director, Menat
MK
Global Director, Pharmacovigilance & Patient ...
TS
Regional Director, Hematology Immunology, Afr...
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sobi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Sobi has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Sobi has new funding data
Product Launch: Get notified when Sobi launches new products
Click to see if Sobi had a recent Job posting/layoffs
Earning: See what the market has to say on Sobi recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Sobi
Check out if Sobi is spiking on competitors!
Sobi, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Sobi is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sobi is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sobi.
Sobi financials insights
Gather financial insights about Sobi, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2011
Stock Offering
$65.4M
2016
Debt
$87.1M
Sobi Tech Stack
A closer look at the technologies used by Sobi
See more technologies
Most Recent Scoops
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Person-Based
Events, Pharmaceuticals
Left Company
Executive Move
Executive Moves, Left Company
Sobi News & Media
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
STOCKHOLM, Sept. 24, 2026 /PRNewswire/ -- Sobi® (STO: SOBI) today announced that new clinical data on Gamifant® (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) will be presented at the 2026 Annual Meeting of the Histiocyte Society (HS2026), taking place 26-29 September...Sobi and Innate announce partnership is now effective following completion of closing conditions
STOCKHOLM, Sept. 16, 2026 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that the previously announced strategic partnership with Innate is now effective following the...Sobi Receives US FDA Fast Track Designation for pacritinib in VEXAS Syndrome
WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to pacritinib for the treatment of VEXAS syndrome. Pacritinib is a dual IRAK1/JAK2 inhibitor currently in Phase ll development for VEXAS syndrome.Sobi has completed an issue of class C shares
STOCKHOLM, Aug. 31, 2026 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued...
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Frequently Asked Questions Regarding Sobi
Sign Up For FreeTo access detailed company insights
Sobi, founded in 2010 and based in Stockholm, Sweden, is an international biopharmaceutical company. Sobi has a research focus on therapies in hematology, immunology, and more.... Read More
